Form 4: REVB Director Jennifer Carver Acquires Company Stock

REVELATION BIOSCIENCES Director Jennifer Carver acquired 15,625 shares of common stock at $1.28 per share through a restricted stock grant.

Summary

• Jennifer Carver, a Director of REVELATION BIOSCIENCES, INC. (REVB), acquired 15,625 shares of common stock.
• The transaction occurred on October 29, 2025, at an acquisition price of $1.28 per share.
• The acquisition was a restricted stock grant under the company's 2021 Equity Incentive Plan.
• These shares will vest 100% on January 28, 2026.
• Following this transaction, Jennifer Carver directly beneficially owns 15,688 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even through a grant, generally signals confidence in the company's future and aligns management's interests with shareholders. The use of a 10b5-1 plan also indicates structured and compliant insider activity.

Positives

• Increased insider ownership by a Director, which can signal confidence in the company's future prospects.
• The acquisition was part of a restricted stock grant, aligning management incentives with shareholder interests.

Future Outlook

The acquired restricted stock grant is scheduled to vest 100% on January 28, 2026, indicating a future milestone for the reporting person's equity ownership.

Industry Context

This insider transaction reflects a standard practice of equity compensation within the biotechnology sector, aiming to align the interests of directors and executives with long-term shareholder value. Such grants are common mechanisms for attracting and retaining talent in growth-oriented industries like biotech.

Comparison to Industry Standards

• Equity incentive plans and restricted stock grants are standard compensation tools across the biotechnology industry, used to incentivize long-term performance and retain key personnel.
• The use of a Rule 10b5-1(c) plan for insider transactions is a common practice among public company executives and directors to establish a pre-arranged trading plan, providing an affirmative defense against insider trading allegations and demonstrating adherence to regulatory best practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling management's commitment and confidence in the company's future.
• Employees: The use of an equity incentive plan demonstrates the company's strategy for attracting and retaining talent through equity compensation.

Next Steps

• The restricted stock grant will vest 100% on January 28, 2026.

Key Dates

Keywords

REVELATION BIOSCIENCES, REVB, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Grant, Director, Equity Incentive Plan, Biotechnology